Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue Followed by 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors

• Status: Completed
• Trial end date: 2017-12-30

Summary

The purpose of this study is to:

Find out how safe and effective (by monitoring the good and/or bad effects) treatment with high dose temozolomide, thiotepa and carboplatin with stem cell rescue followed by 13-cis-retinoic acid has on children and adolescents with recurrent/refractory brain tumors

Find out how the body uses 13-cis-retinoic acid by studying the your blood levels and proteins in the blood that break down the 13-cis-retinoic acid

Determine how well 13-cis-retinoic acid penetrates into the spinal fluid.

• Phase: Phase 2

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Collaborators: Children's Hospitals and Clinics of Minnesota; Schneider Children's Hospital
• Treatments: Carboplatin; Dacarbazine; Isotretinoin; Temozolomide; Thiotepa; Tretinoin